84 results about "Receptor expression" patented technology

The invention discloses a two-dimensional bionic nanostructure assembled based on receptor-ligand acting force and a preparation method of the two-dimensional bionic nanostructure. The core characteristic of the two-dimensional bionic nanostructure is that the ultrafine particles modified by ligand molecules are anchored on the surface of a cell membrane fragment with a corresponding receptor expressed on the surface through a receptor-ligand effect, so that uniform compounding of the ultrafine particles and the cell membrane is realized; the bottlenecks of low compounding efficiency, functional site masking and the like caused by high surface curvature of small-size particles in the traditional cell membrane complete wrapping technology are broken through. According to the preparation method disclosed by the invention, the binding force between the cell membrane and the ultramicro particles is stronger, the off-target phenomenon of the ultramicro particles in the in-vivo circulation process can be avoided, the response release of the ultramicro particles under the competition effect in a lesion region expressed by a high-abundance receptor can be realized, and the preparation method has a good application prospect in the aspect of precise drug delivery. Meanwhile, the in-vivo circulation time of the ultrafine particles is prolonged by membrane loading, the biocompatibility of the ultrafine particles is improved, and the effectiveness and low toxicity of a drug delivery system are ensured.

The invention discloses an experimental method based on depletion-type nk cells as a lung cancer treatment target, and relates to the technical field of bioinformatics. Comprising the following steps: S1, data processing; s2, identification of cell subset characteristic genes and cell type annotation; s3, re-clustering the NK cells; s4, NK cell function annotation; s5, differential gene expression analysis; s6, analyzing the difference of activation and inhibition of receptor expression by the RGS1 + NK cells through single cells; s7, performing quasi-time sequence analysis; s8, carrying out cell culture and siRNA transfection; s9, detecting the expression condition of an NK92mi cell activated receptor after the RGS1 is knocked down; s10, carrying out a lactic dehydrogenase release experiment; s11, measuring the IFN-gamma content of the cell supernatant; and S12, virtual screening of drugs. Through analysis and experimental verification, the key function of RGS1 in NK cell depletion in lung cancer is disclosed, and a new and potential molecular target is provided for lung cancer treatment.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The present disclosure relates to the field of nuclear imaging and therapy, and more particularly, to high purity copper radiotracer compositions that can be used in imaging (e.g., positron emission tomography (PET) and single photon emission computed tomography (SPECT)) and therapy. More specifically, the present disclosure relates to novel compositions useful for imaging and treating conditions (e.g., prostate cancer, somatostatin receptor expressing tumors, such as neuroendocrine tumors, epithelial tumors), and methods of making such compositions.

The present invention inter alia relates to a chimeric transmembrane receptor comprising a polypeptide, wherein the polypeptide comprises at least one T cell immunoreceptor with Ig and ITIM domains (TIGIT) polypeptide region comprising a TIGIT extracellular ligand binding domain; further wherein the polypeptide comprises at least one non-TIGIT polypeptide region, wherein the at least one non-TIGIT polypeptide region comprises a transmembrane polypeptide region of CD2, CD40, HVEM, or CD30, and wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2, CD40, HVEM, or CD30, or wherein the transmembrane domain is from TIGIT and further wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2 or CD28. The invention also relates to corresponding nucleic acids, vectors and T-cells comprising or expressing the chimeric receptors, to a pharmaceutical composition comprising the T-cells, and to methods for preparing a T-cell for immunotherapy and for treating a disease, respectively, wherein the chimeric transmembrane receptor is used.

The invention discloses a method for multi-dimensionally researching synergistic effect among aromas based on human sense-olfaction receptors, which comprises the following steps: firstly, measuring threshold values and interaction effects of aroma substances by using sensory experiments so as to characterize olfaction perception interaction among aroma compounds; constructing an olfactory receptor in-vitro heterologous expression cell model and an olfactory receptor expression element; carrying out olfaction receptor expression and determination; and finally, determining the activation effect of the binary aroma system on the olfactory receptor, and comparing the activation effects of the single substance and the binary system on the receptor so as to research the interaction effect of the aroma compounds at the receptor level. The method is a brand-new method for researching interaction among fragrances from multiple angles based on human sense organs and olfactory receptors, combines the advantages of high integration of human sense organs and high sensitivity of olfactory receptors, makes up for the defect that the interaction of flavor substances can be researched only through human sense organ experiments in the prior art, is intuitive and reliable in shown result, and is suitable for large-scale popularization and application. The applicability is wide.

The present invention relates to novel cell lines for the expression of the human LHCG receptor and for the expression of the human LHCG receptor and a luciferase reporter gene. Methods for producing such cell lines are also described. The cell lines of the present invention, which express the LHCG receptor and a luciferase reporter gene, can be used in methods for determining the presence and biological activity of r-hLH and r-hCG samples.

The invention provides a method for regulating and controlling proliferation and movement of human peripheral blood T cells by Amuc1100 protein. The method relates to the technologies of separation, activation and culture of human peripheral blood T cells, CCK-8 cell proliferation detection, Transwell cell chemotactic detection, flow cytometry receptor expression body detection and the like. The application of the Amuc1100 protein to treat T cells proves that the protein can significantly down-regulate the expression of CD25 and CXCR4 of the T cells and inhibit T cell proliferation and CXCL12 induced T cell chemotactic movement respectively. The method and research means for in-vitro regulation of T cell proliferation and chemotactic movement can be applied to targeted regulation of T cells and directional migration of intestinal tracts of the T cells, and are used for maintaining the steady state of the intestinal tracts, relieving intestinal inflammations and screening drugs to treat diseases related to the intestinal inflammations.

To provide an ophthalmic formulation for treating or preventing glaucoma or pathogenic intraocular pressure.SOLUTION: The ophthalmic formulation comprises a Wnt receptor inhibitor that specifically inhibits expression of a Wnt receptor selected from among frizzled-2 (FZD2), frizzled-5 (FZD5), and receptor tyrosine kinase like orphan receptor 1 (ROR1) through genetic manipulation.SELECTED DRAWING: None

The present invention inter alia relates to a T-cell expressing a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 wildtype receptor, wherein said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95-derived co- stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, OX40, and / or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and / or an IL6-receptor family protein; wherein the T-cell further expresses an engineered T-cell receptor. The present invention also relates to a vector comprising nucleic acids encoding for the CD 95 receptor and the engineered T-cell receptor, as well as to a kit for preparing the T-cells of the present invention, and a pharmaceutical composition comprising the T-cells. The invention also relates to a method for preparing a T-cell for immunotherapy, and to a method for treating a patient having a disease comprising administering the pharmaceutical composition.

This invention discloses a composition and method comprising bis(demethoxycurcumin) enriched in at least 20% w / w for inhibiting receptor for advanced glycation end products (RAGE) expression in subjects with chronic inflammatory conditions. The composition further comprises β-amyrin palmitate (BAP). This invention also discloses the use of the above composition in controlling chronic inflammatory conditions in subjects.

To provide a method for reducing cholesterol.SOLUTION: There is provided an agent which promotes expression of a class B scavenger receptor which is expressed on a lymphatic vessel endothelial cell. The expression decreases with age. More specifically, at least one plant extract selected from the group consisting of a camellia seed extract, a rosemary extract, a Chinese blackberry tea extract, and a citrus unshiu peel extract is identified as a component which promotes the expression of the class B scavenger receptor, resulting in provision of an expression promoter for the scavenger receptor.SELECTED DRAWING: Figure 1

The present invention relates to methods for identifying cancers, responders, predicting a response and stratifying patients with respect to a combination therapy comprising administration of P2X4 receptor inhibitors and cell death inducing chemotherapy. The method according to the present invention identifies cancers, responders, predicts responders and stratifies patients based on detecting the P2X4 receptor protein expression in cells of a patient- derived cancer sample, such as a cell or organoid, wherein an increase in the protein expression identifies cancers, responders, and predicts responders when applying the combination therapy, and further allows to stratify the patients accordingly.

The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

The application discloses a composition for inducing T cell reprogramming into NK-like cells and application thereof. The composition comprises a DNA methyltransferase inhibitor, a histone deacetylase inhibitor and a vitamin C phosphate derivative; the molar ratio of the DNA methyltransferase inhibitor and the vitamin C phosphate derivative is 1: (40-2500); and the final concentration of the histone deacetylase inhibitor is 0.05-2 muM. The vitamin C phosphate derivative is used to replace common vitamin C, and the defects of common vitamin C, such as weak reprogramming promotion effect in a platelet lysate system, limited cell proliferation and low receptor expression, are overcome, so that the composition is more suitable for a clinical serum-free large-scale preparation scene.

The invention discloses a preparation method of brassinolide derived carbon quantum dots and application of the brassinolide derived carbon quantum dots in plant hormone receptor detection. According to the method, BRs is used as a precursor, CQDs with a BRs semi-reserved structure are prepared through co-carbonization with citric acid, and the nano material with the particle size of 3.1 + / -0.5 nm and the surface rich in hydroxyl / keto is obtained after dialysis and purification. When the CQDs are combined with the BRs receptors, the fluorescence intensity of the CQDs is linearly enhanced along with the concentration of the receptors, the nano sensor constructed based on the CQDs can realize rapid quantitative detection of the BRs receptors in rice leaves, the linear range is 0.01-4.0 mg / mL, the detection limit is as low as 0.003 mg / mL, and the sensitivity is improved by 10 times compared with that of ELISA (Enzyme-Linked Immunosorbent Assay). By detecting the receptor expression quantity of a wild type and BRs receptor overexpression strain in a germination period, a heading period and a mature period, it is verified that the result of the strain is highly consistent with that of Western Blot, and the detection time is shortened to 30 minutes. The method does not need targeted modification, has the advantages of high specificity, interference resistance and low cost, and provides an efficient detection tool for rice molecular breeding and stress resistance regulation.

The present invention discloses the use of a reagent for measuring the expression level of discoidin domain receptor 2 (DDR2) in the manufacture of a kit for diagnosing a neurodegenerative disease in a subject, wherein a higher level of DDR2 in a sample derived from the subject than that of a control not affected by the disease indicates that the subject is affected by the neurodegenerative disease. The present invention also discloses a kit, method, and computer-readable medium for diagnosing neurodegenerative diseases. The present invention efficiently and accurately diagnoses neurodegenerative diseases by measuring DDR2.

To provide a novel composition capable of promoting expression of a pleiotrophin receptor.SOLUTION: An agent for enhancing pleiotrophin receptor expression comprising, as an active ingredient, one or two or more plant extracts of plants selected from the group consisting of Ruscus aculeatus, Olea europaea, and Plantago major.SELECTED DRAWING: Figure 2

The present application relates to the use of amphotericin B or its combination in the preparation of anti-tumor drugs. The present application first confirms that amphotericin B directly binds to Toll-like receptor 2 and activates the downstream signaling pathway as a Toll-like receptor 2 agonist, thereby enhancing the phagocytic ability of macrophages to tumor cells; it is first confirmed that amphotericin B combined with therapeutic antibodies can produce a synergistic anti-tumor effect, and the above synergistic effect is mainly due to the regulatory effect of amphotericin B on macrophage function, including enhancing Fc gamma receptor expression and polarizing macrophages to M1 direction, which provides a solid foundation for the clinical transformation of amphotericin B and is expected to provide new treatment options for cancer patients.

The present invention relates to methods for identifying cancers, responders, predicting a response and stratifying patients with respect to a combination therapy comprising administration of P2X4 receptor inhibitors and cell death inducing chemotherapy. The method according to the present invention identifies cancers, responders, predicts responders and stratifies patients based on detecting the P2X4 receptor protein expression in cells of a patientderived cancer sample, such as a cell or organoid, wherein an increase in the protein expression identifies cancers, responders, and predicts responders when applying the combination therapy, and further allows to stratify the patients accordingly.

A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+ / TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed, herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

The invention relates to the technical field of cellular immunotherapy, in particular to a method for amplifying NK cells through combination of an anti-CD52 monoclonal antibody and cell factors and application of the method, and the method comprises the following steps: (1) extracting mononuclear cells PBMCs from peripheral blood of a donor; (2) culturing the mononuclear cells together with an anti-CD52 monoclonal antibody, an anti-CD3 monoclonal antibody and a cytokine composition containing IL-2, IL-15 and IL-21, and performing multiplication culture for 14-21 days under the conditions of 37 + / -1 DEG C and 5 + / -0.5% CO2; (3) amplified cells are harvested, the purity of the CD3-CD56 + NK cells reaches 85% or above, and the number of the cells is increased by 1000 times or above of the number of the original NK cells; and (4) detecting the surface receptor expression and killing activity of the NK cells, and through the synergistic effect of the combination of the anti-CD52 monoclonal antibody and the specific cytokines, the amplification multiple of the NK cells can reach more than 1000 times.

To provide an inhibitor of expression of a receptor for adherence of pneumonia-causing bacteria.SOLUTION: An inhibitor of expression of a receptor for adherence of pneumonia-causing bacteria comprises at least one selected from the group consisting of hesperidin, cinnamaldehyde, citric acid hydrate, L-glutamic acid hydrochloride, and tartaric acid.SELECTED DRAWING: None

The present invention relates to methods for identifying cancer, responders, predicting response and stratifying patients with respect to a combination therapy comprising the administration of a P2X4 receptor inhibitor and a cell death inducing chemotherapy. The methods according to the present invention are based on the detection of P2X4 receptor protein expression in cells of a patient-derived cancer sample, e.g. cells or organoids, to identify cancer, responders, predict responders and stratify patients, wherein an increase in protein expression identifies cancer, responders and predicts responders when applying the combination therapy and also allows to stratify the patients accordingly.

The invention discloses a CCK2R ligand compound, a radiolabeled compound and application thereof, and relates to the technical field of biological medicine. Wherein the structural general formula of the CCK2R ligand compound is shown in the specification; wherein R is a chelating group, and n is an integer from 3 to 5. The CCK2R ligand compound has good CCK2R binding capacity, compared with a tracer agent or a therapeutic agent in the prior art, the radiolabeled compound composed of the CCK2R ligand compound and radionuclide has equivalent or even higher uptake value on tumors expressed by cholecystokinin II type receptors, the in-vivo inhibition effect is remarkable, and the CCK2R ligand compound can be used for preparing the radiolabeled compound for treating the tumors expressed by the cholecystokinin II type receptors. And a new strategy is provided for diagnosis and treatment of tumors with cholecystokinin II type receptor expression.

The present invention discloses a chimeric switch receptor for macrophages and its application, which belongs to the field of biomedicine technology. The chimeric switch receptor for macrophages provided by the present invention includes: an extracellular region, the extracellular region includes the extracellular domain of IL-2α, IL-2β or IL-2γ receptor; a transmembrane region, the transmembrane region includes the transmembrane domain of CD8 or CD28 molecule; an intracellular region, the intracellular region includes the intracellular domain of CD3ζ, TLR4, CD40 or Dectin1 molecule. The chimeric switch receptor of the present invention is expressed on the surface of tumor-associated macrophages, which can induce M2 macrophages to transform towards M1 phenotype after binding of exogenous IL-2 to the chimeric switch receptor on the cell surface, thereby fully exerting the phagocytic and killing effect on tumor cells.

The invention belongs to the technical field of biology, and discloses an influenza B virus sensitizing cell strain as well as a construction method and application thereof. The influenza B virus sensitizing cell strain STX-BB2 can be used for stably expressing influenza virus receptor ST6GAL1 protein in a human source and controllably inducing and expressing influenza B virus PB2 protein by using doxycycline; the preservation number of the cell strain STX-BB2 is GDMCC (China General Microbiological Culture Collection Center) NO: 67100; the cell strain can enhance the expression ability of a host receptor and the virus replication key gene level at the same time; the infection efficiency and the replication titer of the influenza B virus in MDCK cells can be improved; the method can be widely applied to influenza B virus separation, mechanism research, vaccine seed virus amplification and drug screening model construction.

The present invention, as described herein, relates to a novel cell line for expressing the human FSH receptor together with a luciferase reporter gene. Methods for preparing such cell lines are also described. The cell lines of the present invention expressing the FSH receptor and luciferase reporter gene can be used in methods for determining the presence and biological activity of r-FSH samples.